Idorsia is celebrating US approval of its first-in-class hypertension treatment Tryvio – but the cash-strapped company may well have to sell off the rights to the product in order to keep its debtors at bay.
Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?
CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.
More from New Products
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.